Enovis (ENOV) CG 2025 Musculoskeletal Conference summary

Strategic growth and business transformation

• Aggressively expanded reconstructive business from $300M to $1B through innovation and acquisitions, reaching over $2B in total company revenue.

• Prevention and recovery segment maintains strong market position in a $4B–$5B market.

• 2024 marked by the integration of Lima, driving double-digit recon growth and 210 bps margin improvement in Q4.

• 2025 guidance anticipates accelerated growth, further margin expansion, and improved free cash flow.

• CEO transition underway, with a search for a dynamic new leader progressing well.

M&A integration and synergy realization

• Lima acquisition provided complementary strengths, especially in extremities and international markets.

• Achieved $322M contribution from Lima, exceeding expectations, with strong OUS performance.

• Rapid integration in the U.S. minimized disruption; further cost synergies expected from manufacturing consolidation by 2026.

• Diversified business mix: now balanced between Recon/PNR, extremities/large joints, and U.S./OUS.

Market and product innovation

• Shoulder segment rebounding in 2025 after integration-related disruption, supported by new glenoid solutions for bone loss.

• Hip segment addressing portfolio gaps with new direct anterior solutions and plans to introduce successful OUS products to the U.S.

• Foot and Ankle business outpacing market growth, leveraging M&A expertise and innovation in Nitinol-based products.